News - Velcade, Watson Pharmaceuticals

Filter

Popular Filters

1 to 25 of 90 results

UK NICE backs Janssen’s Velcade for multiple myeloma

UK NICE backs Janssen’s Velcade for multiple myeloma

21-03-2014

In new draft guidance published today, UK drugs watchdog the National Institute for Health and Care Excellence…

JanssenJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

Actavis confirms challenge to Allergan’s Restasis

22-01-2014

Generics drug major Actavis has confirmed that its Watson Laboratories unit has submitted an Abbreviated…

ActavisAllerganGenericsNorth AmericaOphthalmicsPatentsRegulationRestasisUSAWatson Pharmaceuticals

NICE seeks more data on J&J’s Velcade for multiple myeloma

NICE seeks more data on J&J’s Velcade for multiple myeloma

12-11-2013

In draft guidance published today, the UK’s drugs watchdog the National Institute of Health and Care…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalPricingRegulationVelcade

EU backs wider use of Velcade

09-08-2013

The European Commission has approved the use of Johnson & Johnson (NYSE: JNJ) European subsidiary Janssen-Cilag's…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationVelcade

Shire prevails in US Lialda patent dispute with Watson

10-05-2013

Ireland-headquartered drugmaker Shire's (LSE: SHP) subsidiary Shire Development has prevailed in its…

ActavisGastro-intestinalsGenericsLegalLialdaNorth AmericaPatentsPharmaceuticalShireWatson Pharmaceuticals

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

Strong results from meta-analysis of Takeda's Velcade in multiple myeloma

08-04-2013

Millennium, the USA-based oncology unit of Japan's largest drugmaker Takeda Pharmaceutical (TSE:4502),…

Millennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

AstraZeneca in Crestor patent settlement with Actavis and EGIS Pharma

25-03-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into a settlement agreement in its US patent…

ActavisCardio-vascularCrestorGenericsNorth AmericaPatentsPharmaceuticalrosuvastatinShionogiWatson Pharmaceuticals

Lower 4th-qtr 2012 profits at Actavis but beat expectations

19-02-2013

US generics major Actavis (NYSE: ACT, the new name for the Watson business) reported net revenue increased…

ActavisFinancialGenericsWatson Pharmaceuticals

Pfizer prevails in Rapamune patent dispute with Watson

01-02-2013

Global pharma behemoth Pfizer (NYSE: PFE) says that the US District Court for the District of Delaware…

ActavisGenericsImmunologicalsLegalNorth AmericaPatentsPfizerPharmaceuticalRapamuneWatson Pharmaceuticals

Watson Pharma now trading as Actavis; Dr Reddy's debuts generic Clarinex Reditabs in USA

28-01-2013

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) announced last week that the company has adopted…

ActavisClarinex ReditabsDr Reddy's LaboratoriesFinancialGenericsManagementMarkets & MarketingWatson Pharmaceuticals

Watson acquires Uteron Pharma; confirms Opana patent challenge

24-01-2013

US generic and specialty drugmaker Watson Pharmaceuticals (NYSE: WPI) says that it has completed the…

Endo PharmaceuticalsGenericsGrunenthalMergers & AcquisitionsNeurologicalNorth AmericaOpanaPatentsPharmaceuticalUteron PharmaWatson PharmaceuticalsWomen's Health

Patent cliff: one drugmaker's sorrow is another one's joy

20-01-2013

The patent cliff has seen many drug majors lose their exclusivity on blockbuster drugs to generic makers…

DilantinGenericsLystedaMarkets & MarketingMylan LaboratoriesNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

New molecule to target pancreatic cancer treatment found by Mayo Clinic researchers

06-01-2013

A new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more…

bortezomibJohnson & JohnsonOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

US Supreme Court agrees to review pay-for-delay generic deals

10-12-2012

The US Supreme Court has agreed to a request by the Federal Trade Commission to look into the practice…

GenericsLegalNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

Watson gains FDA approval for generic Revatio

12-11-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has received approval from the US Food and Drug…

GenericsNorth AmericaPfizerRegulationRespiratory and PulmonaryRevatioWatson Pharmaceuticals

Watson 3rd-qtr EPS jumps 24%, as revenues rise 19%

01-11-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has reported that net income for the third quarter…

ActavisFinancialGenericsWatson Pharmaceuticals

Watson gets FDA final approval for generic Actos; negative news on Prochieve appeal

29-10-2012

US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) said on Friday that it has launched a generic…

ActosDiabetesGenericsLegalMylan LaboratoriesNorth AmericaProchieveRegulationReproductiveTakeda PharmaceuticalsWatson Pharmaceuticals

Forest Labs links with moksha8 for Viibryd in Latin America; Watson sells minority stake

24-10-2012

US drugmaker Forest Laboratories (NYSE: FRX) has entered into a broad strategic alliance with Brazil-based…

Forest LaboratoriesGenericsLicensingMergers & AcquisitionsMoksha8NeurologicalPharmaceuticalSouth AmericaViibrydWatson Pharmaceuticals

1 to 25 of 90 results

Company Spotlight

Fibrotech

Fibrotech

Back to top